About Us
VasoDynamics is a pharmaceutical development company
based in London, UK. We are a young company with young-at-heart executives
and a shared vision to improve the standard of cancer care globally.
​
Recognising the mounting cost pressures facing healthcare payers all over the world, we are developing a number of cost-efficient medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy.
​
We take great pride in our culture of scientific and development rigour, and our programmes are based on robust science from world-leading research bodies.
​
is to develop patient-friendly and preventative and therapies that make a major and positive difference to cancer patients’ well-being and quality of life, with substantial payer savings potential.
​
comprises 3 differentiated radio-protection programmes for topical administration.
​
Our Intellectual Property
is protected by global patents and based on groundbreaking research at University of Wisconsin-Madison in the field of radioprotection.
​
includes executives with decades of individual experience across Medicine, Radiotherapy, Regulatory Affairs, Drug Development and Commercialisation.
​
Our lead programme
NG11 for the prevention of radiotherapy-induced oral mucositis(RIOM) is due to enter clinical trials in 2020